VideoViral Hepatitis and Liver DiseaseHEP DART 2017Update on Merck’s HCV Program | Mike RobertsonView Video
TATarik AsselahMD, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination | Tarik AsselahView Video
JFJordan FeldMD, MPHVideoViral Hepatitis and Liver DiseaseHEP DART 2017DAA Controversies: Do they Cause HBV Reactivation and/or HCC? | Jordan Feld, MD, MPHView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Management of HCV in Decompensated liver disease | Michael MannsView Video
MSMark SulkowskiMDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Clinical Challenges in HCV infection | Mark Sulkowski, MDView Video
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)VideoViral Hepatitis and Liver DiseaseHEP DART 2017SB 9200: A novel RIG-I agonist for chronic hepatitis B | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Development of Immune Competent Small Animal Models for HBV | Helene Strick-MarchandView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Core Antibody: anti-HBc What is the Core of the Story? | Robert Gish, MDView Video
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)VideoViral Hepatitis and Liver DiseaseHEP DART 2017Endpoints and New Targets for Curing Hepatitis B | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Video
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)VideoViral Hepatitis and Liver DiseaseHEP DART 2017Is Host Genome Integrated HBV Relevant? - The Con Perspective | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Video
MPMarion PetersMDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Personalized Approaches to HBV Cure | Marion Peters, MDView Video
AGAdam GehringPhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Immunology of HBV | Adam Gehring, PhDView Video
